retatrutide trial news Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Trial of next-gen weight-loss drug

Based on current data, retatrutide appears to be the strongest weight loss injection studied so far

August 14, 2025 3:59 View More The #1 Hormone Women Arent Testing The Best Way to Protect Fertility & Pregnancy with McCall McPherson In this solo episode of Modern Thyroid Wellness, McCall McPherson, thyroid expert and founder of Modern Thyroid Clinic, explores the critical connection between thyroid health and fertility

MilliporeSigma) i.p

His article on GLP-1 anti-inflammation benefits also explains why inflammation and metabolic health are often evaluated together

Some families may continue breastfeeding with healthcare guidance, while others may delay medication, reduce feeds, or wean